RxDoctor Payments Data

Mark Gomez, MD

Internal Medicine · Naperville, ILNPI 1174728430

Payments from drug & device makers

$1,733in general payments, 2019–2025

Across 58 payments — averaging $29.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$544
  • Boehringer Ingelheim$471
  • Amgen$302
  • AstraZeneca$133
  • Amarin Pharma, Inc.$132
  • Novartis$92
  • plus $60 from 2 others

What the payments were for

  • Food & beverage$1,71599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,733 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$92,584
Medicare patients
158
Services billed
1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide30$51,924
JardianceEmpagliflozin27$40,838
EliquisApixaban17$27,001
MounjaroTirzepatide18$18,570
OzempicSemaglutide18$16,984
XareltoRivaroxaban13$12,386
Breo ElliptaFluticasone/Vilanterol12$4,877
Rosuvastatin Calcium261$3,716
Lagevrio (Eua)Molnupiravir18$3,141
Losartan Potassium134$1,909
Ezetimibe76$1,793
Lansoprazole13$1,709
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,533
Atorvastatin Calcium113$1,500
SynthroidLevothyroxine Sodium25$1,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$30$70,49448 claims
Boehringer IngelheimJardiance$471$40,83827 claims
Novo NordiskOzempic$544$16,98418 claims
Johnson & JohnsonXarelto$30$12,38613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →